| 摘要 |
An implant comprising a hydrogel, octreotide, and a hydrophilic excipient is disclosed, wherein: said octreotide is contained within said hydrogel which comprises a copolymer obtained from the copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers; said implant contains from about 20 to about 150 milligrams of octreotide, in free form or salt form; said implant provides an in vivo average steady state concentration (Css) of about 0.1 ng/ml to about 9 ng/ml of octreotide in a patient over a period of at least about two months; and said hydrophilic excipient is selected from the group consisting of dextran, an hydroxyalkyl cellulose, albumin, and tocopherol propylene glycol succinate. These implants are suitable for subcutaneous administration for the treatment of acromegaly or symptoms associated with acromegaly in a patient in need thereof.
|
